查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1994259

Eylea市场：2026-2032年全球市场预测（依适应症、给药频率、最终用户和通路划分）

Eylea Market by Indication, Dosage Frequency, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，Eylea 市场价值将达到 77.1 亿美元，到 2026 年将成长到 81.9 亿美元，到 2032 年将达到 127.5 亿美元，复合年增长率为 7.45%。

主要市场统计数据
基准年 2025 77.1亿美元
预计年份：2026年 81.9亿美元
预测年份：2032年 127.5亿美元
复合年增长率 (%) 7.45%

本文全面说明了 Eylea 不断变化的临床作用、医疗保健服务的转型以及影响相关人员决策的分销考虑因素。

艾力雅（Eylea）是一种广泛使用的玻璃体内注射抗血管内皮生长因子（VEGF）疗法，由于其在多种适应症中疗效显着，以及支付方和医疗服务提供者不断变化的需求，已成为现代视网膜疾病治疗的核心。临床医师在选择药物时，越来越重视比较给药间隔、作用持续时间和安全性，艾力雅的临床应用也经常在此背景下进行评估。同时，给药场所的变化，从医院门诊到门诊手术中心，以及眼科诊所在常规注射中作用的不断增强，正在重塑治疗管道。

对受技术进步、保险公司加强监管以及临床环境变化等因素影响的市场变革进行详细分析，这些变革影响了 Eylea 的使用。

随着技术创新、支付方趋势以及临床环境的经济因素重塑治疗方法的选择和实施方式，视网膜治疗市场格局正经历变革性的变化。新的影像技术和真实世界数据正在完善启动治疗的标准，并促成更个人化的给药决策，进而影响诊所的接诊能力和病患追踪频率。同时，支付方正在加强对用药模式和预核准流程的监控，这影响着药物製剂的选择和在保险覆盖范围内的定位。

详细检验2025 年美国关税将如何影响视网膜治疗药物的供应链、筹资策略和分销稳定性。

关税和贸易措施的推出会对药品供应链、筹资策略和价格谈判产生连锁反应。 2025年，美国关税调整影响了製造商和经销商的库存规划、合约谈判和进口策略制定，促使他们重新评估成本因素和紧急应变计画。这些政策变化导致供应商选择受到更严格的监管，并加速了关于本地化生产和近岸外包以降低跨境风险的讨论。

实用的细分见解阐明了适应症、治疗地点、分销管道和给药频率如何影响 Eylea 的临床引入和运作策略。

细分市场分析揭示了微妙的市场接受模式和营运影响，有助于临床、商业和供应链决策。就适应症而言，Eylea在老龄化黄斑部病变、视网膜分支静脉阻塞症、视网膜中央静脉阻塞、糖尿病性黄斑部水肿和糖尿病视网膜病变的应用各有其独特的患者特征、监测要求和长期管理目标，这些因素都会影响治疗间隔和随访频率。例如，慢性糖尿病视网膜疾病的治疗通常需要与内分泌科医生和基层医疗密切合作，而静脉阻塞病例可能需要更频繁的干预和基于影像学的追踪。

基于整合美洲、欧洲、中东和非洲以及亚太地区在监管、保险公司和医疗保健服务体系方面的差异的关键区域信息，我们制定针对每个地区的战略。

区域趋势对监管流程、支付方结构和临床实务规范有显着影响，因此需要采取在地化的商业化和存取策略。在美洲，视网膜领域的集中专业知识和多样化的支付方模式有利于高品质证据的产生和复杂合约谈判，而区域分销中心和库存弹性对于供应链至关重要。同时，在欧洲、中东和非洲，不同的法规结构和定价机制要求差异化的策略，以促进与国家卫生部门和私人保险公司的对话。

企业层面的洞察，聚焦在视网膜治疗领域透过综合服务交付实现的证据产生、供应链韧性和策略差异化。

视网膜治疗领域的竞争格局呈现出成熟生物製药、生物相似药和新兴给药技术并存的局面，促使各公司优先考虑透过疗效数据、患者支持和供应稳定性来实现差异化。主要企业正投资于直接比较试验、真实世界数据 (RWE) 生成和疗效註册研究，以证明其临床优势并支持与支付方的对话。同时，各公司正透过提供可减轻临床医生和患者行政负担的服务来强化其商业性提案，例如简化核准前流程和协调注射治疗流程。

为行业领导者提供实用建议，以协调临床证据、供应弹性和支付方参与，同时优化区域和实践特定策略。

行业领导者必须采取积极措施，使临床价值与营运可行性和支付方预期保持一致，从而维持医疗服务的可及性并优化患者疗效。首先，应加强销售、医学事务和供应链团队之间的跨职能协作，确保合约条款、库存策略和临床讯息的一致性，并能够快速应对价格和采购趋势的变化。这种整合式方法可以降低供应中断的风险，并在政策或物流发生变化时明确责任归属。

我们采用清晰且可重复的调查方法，结合一手访谈、文献整合和情境分析，严格评估临床和营运趋势。

本研究整合了多方面的证据，对临床、营运和商业性趋势进行了全面评估。主要调查包括对视网膜专家、药房采购经理和医疗系统管理人员进行结构化访谈，以了解第一线观点对给药间隔、临床应用趋势和分销挑战的看法。次要调查回顾了同行评审的文献、监管文件和公开的临床实验室结果，以检验每种适应症（包括老龄化黄斑部病变和糖尿病视网膜病变）的临床终点和安全性。

为了指导策略决策，确保患者能够持续获得治疗价值，我们提供了简洁的结论，这些结论整合了关键的临床、营运和区域问题。

总之，Eylea在现代视网膜疾病管理中发挥核心作用，其临床证据和给药模式也不断发展。给药频率偏好、临床环境变化以及分销管道的改变，都为製药公司、医疗服务提供者和保险公司带来了挑战和机会。应对这种复杂的环境需要製定一项整合证据产生、供应链韧性和与保险公司进行有针对性沟通的策略。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：艾力亚市场：依适应症划分

  • 老龄化黄斑部病变
  • 视网膜分支静脉阻塞症
  • 中心性视网膜静脉阻塞
  • 糖尿病黄斑部水肿
  • 糖尿病视网膜病变

第九章：艾力达市场：依给药频率划分

  • 根据需要
  • 每隔一个月
  • 每月

第十章：艾利亚市场：依最终用户划分

  • 门诊手术中心
  • 医院
  • 眼科诊所

第十一章：艾利亚市场：按分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：艾利亚市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：艾利亚市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：艾利亚市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国Eilea市场

第十六章：中国的Eilea市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc
  • Adverum BIoTechnologies Inc
  • Alcon Inc
  • Amgen Inc
  • Apellis Pharmaceuticals Inc
  • AstraZeneca plc
  • Bausch Health Companies Inc
  • Bayer AG
  • Biogen Inc
  • Eli Lilly and Company
  • Genentech Inc
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Kodiak Sciences Inc
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd
  • Outlook Therapeutics Inc
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Roche Holding AG
  • Samsung Bioepis Co., Ltd
  • Sanofi SA
  • Santen Pharmaceutical Co., Ltd
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-1A1A064C04F0

The Eylea Market was valued at USD 7.71 billion in 2025 and is projected to grow to USD 8.19 billion in 2026, with a CAGR of 7.45%, reaching USD 12.75 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.71 billion
Estimated Year [2026] USD 8.19 billion
Forecast Year [2032] USD 12.75 billion
CAGR (%) 7.45%

A comprehensive introduction framing Eylea's evolving clinical role, care delivery shifts, and distribution considerations shaping stakeholder decision-making

Eylea, a widely used intravitreal anti-VEGF therapy, has become central to contemporary retinal disease management due to its established efficacy across multiple indications and evolving payer and provider dynamics. Clinicians increasingly weigh comparative dosing cadence, durability, and safety profiles when choosing between available agents, and Eylea's clinical portfolio is routinely evaluated in that context. Concurrently, changes in delivery settings, from hospital-based clinics to ambulatory surgical centers, and the growing role of ophthalmic clinics in routine injections are reshaping care pathways.

Regulatory approvals and label extensions have expanded Eylea's footprint across indications such as Age-Related Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Diabetic Macular Edema, and Diabetic Retinopathy, prompting shifts in treatment algorithms. Meanwhile, distribution dynamics spanning hospital pharmacy, online pharmacy, and retail pharmacy channels influence how institutions procure and dispense therapies. As stakeholders reassess supply arrangements and clinic workflows, an evidence-based understanding of dosing frequency patterns-spanning as needed, bimonthly, and monthly regimens-becomes essential for operational planning and patient adherence strategies.

In this introduction, the focus is to set the stage for deeper analysis by outlining the clinical, operational, and commercial forces that drive Eylea's adoption. By connecting clinical evidence to care delivery realities and distribution structures, readers can better appreciate the levers available to improve patient outcomes while maintaining fiscal and operational resilience.

An in-depth analysis of transformative market shifts driven by technological advances, evolving payer scrutiny, and site-of-care migration impacting Eylea utilization

The landscape for retinal therapeutics is undergoing transformative shifts as technological innovation, payer behavior, and site-of-care economics converge to reshape how therapies are selected and delivered. Newer imaging modalities and real-world evidence are refining treatment thresholds and enabling more personalized dosing decisions, which in turn affect clinic throughput and the cadence of patient follow-up. In parallel, payers are intensifying scrutiny on utilization patterns and prior authorization processes, influencing prescribing behavior and formulary positioning.

Operationally, the migration of procedures to ambulatory surgical centers and specialized ophthalmic clinics has altered cost structures and patient access dynamics. These site-of-care changes create opportunities for efficiencies but also introduce complexities in inventory management across hospital pharmacy, online pharmacy, and retail pharmacy channels. Moreover, evolving expectations around treatment durability have elevated the importance of dosing frequency choices; options ranging from as needed, bimonthly, to monthly regimens carry implications for adherence, clinic capacity, and long-term visual outcomes.

Collectively, these shifts demand that manufacturers, providers, and payers adopt a more integrated approach to strategy-one that aligns clinical evidence with distribution logistics, contractual terms, and patient support programs. Only through this integrated lens can stakeholders navigate the changing therapeutic ecosystem and identify sustainable pathways to deliver value.

A focused examination of how United States tariffs in 2025 reshaped pharmaceutical supply chains, procurement strategies, and distribution stability for retinal therapies

The introduction of tariffs and trade measures can create ripple effects across pharmaceutical supply chains, procurement strategies, and pricing negotiations. In 2025, United States tariff adjustments influenced how manufacturers and distributors planned inventory, negotiated contracts, and structured their import strategies, prompting a reassessment of cost drivers and contingency mechanisms. These policy changes contributed to elevated scrutiny of sourcing locations and accelerated discussions about regional manufacturing and nearshoring as ways to mitigate cross-border exposures.

As a result, contract negotiations between suppliers and health systems incorporated greater emphasis on supply-chain resiliency and clauses that address tariff pass-through, lead-time variability, and currency exposure. Distribution channels including hospital pharmacy, online pharmacy, and retail pharmacy adapted their procurement strategies to ensure continuity of supply, which in turn affected stockpile policies and fulfillment models. Clinicians saw changes in availability rhythms that required flexible scheduling and patient communication tactics to preserve adherence and outcomes.

Importantly, these tariff-related dynamics intersected with broader shifts in site of care, dosing frequency preferences, and payer reimbursement practices. Consequently, healthcare stakeholders placed a premium on transparency in cost composition and a stronger alignment between commercial teams and supply-chain functions to safeguard patient access while maintaining operational predictability.

Actionable segmentation insights revealing how indication, site of care, distribution channel, and dosing frequency shape clinical adoption and operational strategies for Eylea

Segmentation analysis illuminates nuanced adoption patterns and operational implications that inform clinical, commercial, and supply-chain decisions. Based on indication, Eylea's use spans Age-Related Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Diabetic Macular Edema, and Diabetic Retinopathy, each presenting distinct patient profiles, monitoring requirements, and long-term management goals that influence treatment cadence and follow-up intensity. For instance, chronic diabetic retinal disease pathways often require closer systemic coordination with endocrinology and primary care, whereas vein occlusion cases may demand more episodic intervention and imaging follow-up.

Based on end user, the market is examined across ambulatory surgical centers, hospitals, and ophthalmic clinics, with each setting presenting specific throughput constraints, staffing models, and reimbursement environments that affect regimen selection and scheduling. Distribution channel analysis encompasses hospital pharmacy, online pharmacy, and retail pharmacy, and highlights how procurement lead times, cold-chain logistics, and dispensing workflows shape clinic inventory practices and patient access points. Finally, dosing frequency segmentation considers as needed, bimonthly, and monthly approaches, which carry direct implications for adherence, clinic capacity, and long-term visual stability.

Taken together, these segmentation lenses reveal that strategic choices-ranging from contracting approaches to patient support services-must be tailored to the clinical indication, the primary site of administration, the chosen distribution pathway, and the dosing cadence to ensure both clinical effectiveness and operational efficiency.

Key regional intelligence synthesizing regulatory, payer, and delivery system differences across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform tailored strategies

Regional dynamics exert powerful influence over regulatory pathways, payer structures, and clinical practice norms, requiring tailored approaches to commercialization and access. In the Americas, concentrated centers of retinal expertise and diverse payer models drive both high standards of evidence generation and complex contracting conversations, while supply-chain considerations emphasize regional distribution hubs and inventory resilience. Meanwhile, Europe, Middle East & Africa present a mosaic of regulatory frameworks and pricing mechanisms that necessitate differentiated engagement strategies with national health authorities and private payers.

In Asia-Pacific, rapid modernization of ophthalmic services, expanding private clinic networks, and growing investment in diagnostic infrastructure are accelerating adoption trajectories, yet heterogeneity in reimbursement and procurement processes requires nuanced market access planning. Across these regions, variations in predominant sites of care-ranging from hospital-centric models to ambulatory surgical centers and specialized ophthalmic clinics-alter operational priorities and influence decisions around dosing frequency and patient monitoring.

Consequently, a regionalized strategy that integrates regulatory intelligence, payer engagement, and localized patient support models is essential. By aligning clinical evidence with regional healthcare delivery realities and distribution capabilities, stakeholders can better navigate access barriers, optimize deployment of resources, and support consistent patient outcomes across diverse health systems.

Company level insights highlighting strategic differentiation through evidence generation, supply-chain resilience, and integrated service offerings in the retinal therapeutics space

Competitive dynamics in the retinal therapeutics space reflect a mixture of established biologics, biosimilars, and evolving delivery technologies, prompting companies to prioritize differentiation through outcomes data, patient support, and supply stability. Leading manufacturers have invested in head-to-head comparative studies, real-world evidence generation, and outcomes registries to substantiate clinical advantages and to inform payer conversations. Meanwhile, companies are strengthening their commercial propositions with services that reduce administrative burden for clinicians and patients, such as streamlined prior authorization support and coordinated injection visit pathways.

Supply-chain robustness has become a core differentiator, with industry players emphasizing multiple sourcing options, cold-chain integrity, and contractual flexibility to limit disruption from geopolitical or tariff-related shocks. Strategic partnerships between manufacturers and specialty distributors have surfaced as a method to optimize reach across hospital pharmacy, online pharmacy, and retail pharmacy channels while maintaining compliance with storage and handling requirements. Additionally, investment in digital tools for patient engagement and adherence monitoring is enhancing long-term outcomes and shaping competitive positioning.

Collectively, these company-level activities underscore a broader shift toward integrated solutions that combine clinical evidence, operational reliability, and services that reduce friction in the care pathway. For stakeholders, discerning these strategic priorities is essential when evaluating potential collaborators or benchmarking internal capabilities.

Actionable recommendations for industry leaders to align clinical evidence, supply resilience, and payer engagement while optimizing regional and site-of-care strategies

Industry leaders must take proactive steps to align clinical value with operational feasibility and payer expectations in order to sustain access and optimize patient outcomes. First, strengthen cross-functional alignment between commercial, medical affairs, and supply-chain teams to ensure that contracting terms, inventory strategies, and clinical messaging are coherent and responsive to tariff and procurement dynamics. This integrated approach reduces the risk of supply interruptions and clarifies responsibilities during periods of policy or logistical change.

Second, invest in robust real-world evidence programs and outcomes registries that demonstrate long-term visual benefits and inform payer discussions across indications such as Age-Related Macular Degeneration and Diabetic Macular Edema. Third, tailor patient support and adherence initiatives to dosing frequency realities-whether as needed, bimonthly, or monthly-to sustain visual gains while minimizing no-show rates and clinic bottlenecks. Fourth, expand distribution flexibility by cultivating relationships with hospital pharmacy, online pharmacy, and retail pharmacy partners to diversify fulfillment options and improve patient access points.

Finally, adopt a regionalized go-to-market posture that accounts for differences across the Americas, Europe, Middle East & Africa, and Asia-Pacific, aligning regulatory engagement, reimbursement strategies, and local stakeholder outreach. By operationalizing these recommendations, organizations can build resilience, demonstrate value, and accelerate appropriate patient access.

A clear and reproducible research methodology combining primary interviews, literature synthesis, and scenario analysis to ensure rigorous evaluation of clinical and operational dynamics

This research integrates multiple evidence streams to produce a comprehensive assessment of clinical, operational, and commercial dynamics. Primary research included structured interviews with retina specialists, pharmacy procurement managers, and health system operations leaders to capture firsthand perspectives on dosing cadence, site-of-care trends, and distribution challenges. Secondary research encompassed review of peer-reviewed literature, regulatory documentation, and publicly available clinical trial results to validate clinical endpoints and safety profiles across indications including Age-Related Macular Degeneration and Diabetic Retinopathy.

Analytical methods combined qualitative synthesis with comparative scenario analysis to explore implications of dosing frequency choices-spanning as needed, bimonthly, and monthly regimens-and to assess distribution channel impacts across hospital pharmacy, online pharmacy, and retail pharmacy pathways. Regional context was developed through targeted interviews and regulatory reviews across the Americas, Europe, Middle East & Africa, and Asia-Pacific to ensure findings reflect local practice patterns and access constraints. Throughout, rigorous quality control processes were applied to reconcile divergent inputs and to ensure that conclusions are grounded in verifiable evidence.

Transparency around methodology ensures that readers can interpret findings in light of data sources and analytical assumptions. For organizations seeking customized outputs, the methodology can be adapted to incorporate proprietary datasets, expanded primary interviews, or focused country-level appendices to support specific strategic decision needs.

A concise conclusion synthesizing clinical, operational, and regional imperatives to guide strategic decision-making for sustained patient access and therapeutic value

In conclusion, Eylea occupies a central role in contemporary retinal disease management, with clinical evidence and delivery models continuing to evolve in tandem. The interplay between dosing frequency preferences, site-of-care shifts, and distribution channel dynamics creates both challenges and opportunities for manufacturers, providers, and payers. Navigating this complex environment requires integrated strategies that bring together evidence generation, supply-chain resilience, and targeted payer engagement.

Moreover, regionally tailored approaches that acknowledge the distinct regulatory, reimbursement, and delivery realities across the Americas, Europe, Middle East & Africa, and Asia-Pacific will be essential for sustaining access and improving patient outcomes. As tariff and policy landscapes change, organizations must prioritize transparency in procurement and contractual arrangements to mitigate risk. By implementing the recommended actions-strengthening cross-functional coordination, investing in real-world evidence, diversifying distribution relationships, and adapting to regional nuances-stakeholders can preserve continuity of care and enhance long-term therapeutic value.

Ultimately, decision-makers who synthesize clinical insights with operational readiness will be best positioned to support patients and health systems through a period of continued transformation in retinal therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Eylea Market, by Indication

  • 8.1. Age-Related Macular Degeneration
  • 8.2. Branch Retinal Vein Occlusion
  • 8.3. Central Retinal Vein Occlusion
  • 8.4. Diabetic Macular Edema
  • 8.5. Diabetic Retinopathy

9. Eylea Market, by Dosage Frequency

  • 9.1. As Needed
  • 9.2. Bimonthly
  • 9.3. Monthly

10. Eylea Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Ophthalmic Clinics

11. Eylea Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Eylea Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Eylea Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Eylea Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Eylea Market

16. China Eylea Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc
  • 17.6. Adverum Biotechnologies Inc
  • 17.7. Alcon Inc
  • 17.8. Amgen Inc
  • 17.9. Apellis Pharmaceuticals Inc
  • 17.10. AstraZeneca plc
  • 17.11. Bausch Health Companies Inc
  • 17.12. Bayer AG
  • 17.13. Biogen Inc
  • 17.14. Eli Lilly and Company
  • 17.15. Genentech Inc
  • 17.16. GlaxoSmithKline plc
  • 17.17. Johnson & Johnson
  • 17.18. Kodiak Sciences Inc
  • 17.19. Merck & Co., Inc.
  • 17.20. Novartis AG
  • 17.21. Ono Pharmaceutical Co., Ltd
  • 17.22. Outlook Therapeutics Inc
  • 17.23. Pfizer Inc
  • 17.24. Regeneron Pharmaceuticals Inc
  • 17.25. Roche Holding AG
  • 17.26. Samsung Bioepis Co., Ltd
  • 17.27. Sanofi S.A.
  • 17.28. Santen Pharmaceutical Co., Ltd
  • 17.29. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL EYLEA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EYLEA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EYLEA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EYLEA MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EYLEA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EYLEA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EYLEA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EYLEA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES EYLEA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA EYLEA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EYLEA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EYLEA MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EYLEA MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EYLEA MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EYLEA MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EYLEA MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EYLEA MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EYLEA MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EYLEA MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EYLEA MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EYLEA MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EYLEA MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EYLEA MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EYLEA MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EYLEA MARKET SIZE, BY DIABETIC RETINOPATHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EYLEA MARKET SIZE, BY DIABETIC RETINOPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EYLEA MARKET SIZE, BY AS NEEDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EYLEA MARKET SIZE, BY AS NEEDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EYLEA MARKET SIZE, BY AS NEEDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EYLEA MARKET SIZE, BY BIMONTHLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EYLEA MARKET SIZE, BY BIMONTHLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EYLEA MARKET SIZE, BY BIMONTHLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EYLEA MARKET SIZE, BY MONTHLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EYLEA MARKET SIZE, BY MONTHLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EYLEA MARKET SIZE, BY MONTHLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EYLEA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EYLEA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EYLEA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EYLEA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EYLEA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EYLEA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EYLEA MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EYLEA MARKET SIZE, BY OPHTHALMIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EYLEA MARKET SIZE, BY OPHTHALMIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EYLEA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EYLEA MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EYLEA MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EYLEA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EYLEA MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EYLEA MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EYLEA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EYLEA MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EYLEA MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EYLEA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS EYLEA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EYLEA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GCC EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GCC EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. GCC EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 98. GCC EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GCC EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. BRICS EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. G7 EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. G7 EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. G7 EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 113. G7 EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. G7 EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. NATO EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NATO EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. NATO EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 118. NATO EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. NATO EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. UNITED STATES EYLEA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. UNITED STATES EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. UNITED STATES EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED STATES EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED STATES EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. CHINA EYLEA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. CHINA EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. CHINA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 129. CHINA EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. CHINA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)